Posted in | Laser | Medical Optics

Spectranetics Expands Turbo Elite Laser Atherectomy Catheter Product Line

The Spectranetics Corporation today announced the launch of the Turbo Elite® .035 product line extension. The two new catheter sizes – with diameters of 2.3 mm and 2.5 mm – are compatible with a .035" guidewire, augmenting the versatility of the Turbo Elite laser to treat complex lesions including chronic total occlusions (CTOs) in blood vessels above and below the knee.

The Turbo Elite laser atherectomy catheter was designed specifically for the treatment of Peripheral Artery Disease (PAD), vaporizing blockages in leg vessels and restoring blood flow. The minimally invasive procedure requires less recovery time than bypass surgery and often provides patients with an alternative to amputation.

Vascular surgeon Lawrence J. Goldstein, MD, FACS, participated in clinical evaluations which were conducted at selected regional sites in the U.S. and Europe. He reports consistently saving time and resources when performing crossing procedures with the Turbo Elite system. According to Dr. Goldstein, "I typically attempt to cross an occlusion by first using a .035 guidewire. Because these new catheter sizes are compatible with this wire size, they eliminate the need to change wires to perform the laser atherectomy procedure once I have crossed the lesion."

According to Donna Ford-Serbu, Senior Vice President Global Marketing, Strategy and Portfolio, the Turbo Elite .035 system enables clinicians to cross what is often considered an 'uncrossable' lesion without using a wire. These lesion types are frequently encountered in complex chronic total occlusions, which are reported in up to 40% of patients with peripheral lesions caused by PAD, leaving interventionalists with few treatment options.

"Using a step-by-step lasing technique*, the Turbo Elite .035 can be used to cross a CTO without a guidewire," said Ms. Ford-Serbu. "These new catheters will help fill a need expressed by many interventionalists: more CTO crossing tools. They now have a broader range of versatility that offers safe, proven solutions for patients."

Giancarlo Biamino, MD, Ph.D., Professor of Medicine and Director a.D. of Clinical and Interventional Angiology at the Heart Centre Leipzig in Leipzig, Germany, participated in early physician training on the Turbo Elite .035. A pioneer in the use of laser technology for debulking diseased vessels introducing the step-by-step technique, Dr. Biamino welcomes the addition to the Turbo Elite product line. "One of the biggest concerns in crossing a CTO in the superficial femoral artery is the potential to exit the true lumen and end up in the subintimal space. The Turbo Elite .035 offers a crossing device with true atherectomy and better guidewire support, ensuring effective treatment within the affected lumen of the vessel."

The Turbo Elite .035 represents the latest addition to Spectranetics' CTO solutions portfolio. The company's Quick-Cross® Support Catheter is the world's market leader. Earlier this year, the company introduced the Quick-Access® Needle Holder and Quick-Cross Capture® Guidewire Retriever, completing a portfolio of antegrade and retrograde crossing tools.

Spectranetics will continue to offer extensive physician training events and opportunities throughout 2013 to support procedural success using the new catheters and the other crossing tools that have recently been introduced.

*Lawrence JB, Prevosti LG, Kramer WS, Smith PD, Bonner RF, Lu DY, Leon MB. Pulsed laser and thermal ablation of atherosclerotic plaque: morphometrically defined surface thrombogenicity in studies using an annular perfusion chamber. J Am Coll Cardiol. 1992;19:1091

Source: http://www.spectranetics.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit